New hope for kids with leukemia: smarter chemo dosing could boost cures

NCT ID NCT03020030

Ongoing ⭐️ CURE ⭐️ Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This study tests a new way to treat children and teens with acute lymphoblastic leukemia (ALL), the most common childhood cancer. Researchers are using updated risk factors to decide how strong chemotherapy should be and adjusting doses of a key drug based on blood levels. The goal is to improve cure rates while reducing side effects. About 560 participants will be followed for several years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia childhood acute lymphoblastic leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA, PEDIATRIC

Contacts and locations

Locations

Boston Children's Hospital

Boston, Massachusetts, 02115, United States
Centre Hospitalier U. de Quebec

Québec, Quebec, Canada
Columbia University Medical Center, Morgan Stanley Children's Hospital of New York-Presbyterian

New York, New York, 10032, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Hasbro Children's Hospital / Rhode Island Hospital

Providence, Rhode Island, 02903, United States
Hospital Sainte Justine, University of Montreal

Montreal, Quebec, Canada
Montefiore Medical Center

The Bronx, New York, 10467, United States
Roswell Park Cancer Institute

Buffalo, New York, 14263, United States
Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.